Physician profile
Simon Prince
NPI 1770589285
$12,275.85
in general payments reported to CMS, 2019-2025
29 companies · $600 in 2025
The $600 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,608 · 2020: $7,142 · 2021: $2,118 · 2022: $382 · 2023: $49.49 · 2024: $377 · 2025: $600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,026.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,026.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $7,514.84 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,421.48 | 2021-2024 | |
| Vifor Pharma, INC. | $548.48 | 2019-2025 | Veltassa |
| Otsuka America Pharmaceutical, INC. | $445.43 | 2019-2021 | |
| Horizon Therapeutics Plc | $437.48 | 2019-2021 | |
| Nxstage Medical, INC. | $232.13 | 2022-2024 | |
| Mallinckrodt Hospital Products INC. | $181.78 | 2020-2025 | Acthar |
| Nevro Corp. | $180.28 | 2024 | Senza |
| Opko Pharmaceuticals, LLC | $172.53 | 2019-2025 | Rayaldee |
| Novo Nordisk INC | $170.28 | 2024-2025 | Ozempic, Rybelsus |
| Daiichi Sankyo INC. | $169.05 | 2019-2020 | |
| Aurinia Pharma U.S., INC. | $134.73 | 2021 | |
| Amgen INC. | $122.19 | 2025 | Krystexxa |
| Akebia Therapeutics INC | $96.93 | 2019-2021 | |
| Fresenius USA Marketing, INC. | $72.44 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $66.47 | 2019 | |
| Lundbeck LLC | $41.09 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.98 | 2019-2020 | |
| Abbvie INC. | $34.57 | 2025 | |
| Bard Peripheral Vascular, INC. | $33.07 | 2020 | |
| Pfizer INC. | $23.60 | 2024 | |
| Shire North American Group INC | $23.23 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $20.61 | 2019 | |
| Novartis Pharmaceuticals Corporation | $19.23 | 2021 | |
| Chiesi USA, INC. | $17.47 | 2019 | |
| Boston Scientific Corporation | $16.94 | 2021 | |
| Janssen Pharmaceuticals, INC | $16.61 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.40 | 2021 | |
| Seqirus USA INC | $11.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simon Prince listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.